Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Ozempic for Treatment of T2D

Novo Nordisk news release; 2017 Dec 5

The FDA has approved Ozempic (semaglutide) injection for the treatment of adults with type 2 diabetes.

Indications: Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.

Dosage and administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. Administer once weekly at any time of day, with or without meals. If a dose is missed, administer within 5 days of missed dose.

Adverse reactions: The most common adverse reactions (≥5% of patients) are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Citation:

Novo Nordisk receives FDA approval of OZEMPIC (semaglutide) injection for the treatment of adults with type 2 diabetes. [news release]. Novo Nordisk; Plainsboro, NJ; December 5, 2017. http://press.novonordisk-us.com/2017-12-5-Novo-Nordisk-Receives-FDA-Appr.... Accessed December 8, 2017.

This Week's Must Reads

ACS Recommends CRC Screening at Age 45, CA Cancer J Clin; ePub 2018 May 30; Wolf, et al

ACP Position on Women’s Health Challenges, Ann Intern Med; ePub 2018 May 29; Daniel, et al

Lung Cancer Incidence in Young Men & Women, N Engl J Med; 2018 May 24; Jemal, et al

Aspirin Benefit in Adverse Pregnancy Outcomes, Hypertension; ePub 2018 May 25; Hauspurg, et al

Monitoring NT-proBNP in Patients with Diabetes, Diabetes Care; ePub 2018 May 30; Jarolim, et al

Must Reads in Diabetes

Monitoring NT-proBNP in Patients with Diabetes, Diabetes Care; ePub 2018 May 30; Jarolim, et al

Trends in Diabetes-Related Mortality in the US, Lancet; ePub 2018 May 18; Gregg, Cheng, et al

Plasma Methylglyoxal Levels & Diabetic CVD, Diabetes Care; ePub 2018 May 21; Hanssen, et al

Risk of T2D Among Lesbian and Bisexual Women, Diabetes Care; ePub 2018 May 2; Corliss, et al

Prevalence of Diabetes in the US by Type, MMWR; 2018 Mar 30; Bullard, Cowie, et al